FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Luly Jay R.</u>						2. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC [ENTA]								5. Relationship of Reporting Check all applicable) X Director		g Pers	son(s) to Iss 10% Ov	
	(First) (Middle) ANTA PHARMACEUTICALS, INC. ENAL STREET					3. Date of Earliest Transaction (Month/Day/Year) 05/10/2016								X Officer (give title below) Other (specify below) President and CEO				pecify
(Street) WATERTOWN MA 02472 (City) (State) (Zip)				_ 4. I _	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(0.0)				n-Deri	vativ	e Se	curit	ties Ac	guired,	Dis	posed o	of, or Be	neficial	ly Owned	<u> </u>			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				saction	ction 2/ Exay/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		5. Amou Securitie Benefici Owned F	es Fo ally (D Following (I)		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Reporter Transact (Instr. 3	tion(s)			(Instr. 4)
Common Stock 05/10/2						016		M		25,000) A	\$2.973	588	588,654		D		
			Table II -								osed of, converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	oate, Transa Code		of Deri Sec Acq (A) o Disp of (I	umber vative urities uired or oosed O) (Instr. and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to	\$2.9739	05/10/2016			M			25,000	(1)		07/11/2017	Common Stock	25,000	\$0	41,645	5	D	

Explanation of Responses:

1. 100% of the shares subject to the option are fully vested and exercisable.

Remarks:

/s/ Nathaniel S. Gardiner as attorney-in-fact

** Signature of Reporting Person Date

05/10/2016

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.